RBC Cuts PTC Therapeutics (PTCT) Price Target by Nearly 20%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
Jefferies Cuts PTC Therapeutics (PTCT) Target to $8
March 1, 2016 9:13 AM ESTJefferies analyst, Gena Wang, cut her PT on TC Therapeutics (NASDAQ: PTCT) after hearing more color on the RTF letter and German pricing status on the 4Q15 earnings call. Consistent with her thesis, the FDA questioned ataluren effectiveness in DMD leaving... More
Wedbush Downgrades PTC Therapeutics (PTCT) to Neutral
March 1, 2016 7:29 AM ESTWedbush downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Neutral with a price target of $11.00 (from $27.00), saying lower Translarna estimates shift risk/reward.
Analyst Heather Behanna commented, "Though we still believe Translarna has a good chance of full EU approval, we are... More
Cowen Downgrades PTC Therapeutics (PTCT) to Market Perform
March 1, 2016 7:27 AM ESTCowen downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.
Shares of PTC Therapeutics closed at $7.98 yesterday.
... MorePTC Therapeutics (PTCT) Misses Q4 EPS by 25c
February 29, 2016 4:02 PM ESTPTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($1.50), $0.25 worse than the analyst estimate of ($1.25). Revenue for the quarter came in at $12.7 million versus the consensus estimate of $13.2 million.
The company also offered the following updates:
Refuse to File letter received from the FDA regarding Translarna for nonsense mutation Duchenne muscular dystrophy (nmDMD). The letter from the U.S. Food and Drug Administration (FDA)... More